The finding that venetoclax could be more effective on IDH mutant cells represents a turning point in the prognosis of AML as the stability of IDH mutations during disease evolution suggests that a population of IDH1/2 mutant cells can survive initial chemotherapy and contribute to relapse [92,93]. The gene discussed is IDH2; the disease is acute myeloid leukemia.